JP2014504150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504150A5 JP2014504150A5 JP2013536936A JP2013536936A JP2014504150A5 JP 2014504150 A5 JP2014504150 A5 JP 2014504150A5 JP 2013536936 A JP2013536936 A JP 2013536936A JP 2013536936 A JP2013536936 A JP 2013536936A JP 2014504150 A5 JP2014504150 A5 JP 2014504150A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cells
- item
- human
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 5
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 108091007494 Nucleic acid- binding domains Proteins 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 claims description 2
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 210000004216 mammary stem cell Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000004931 aggregating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45612710P | 2010-11-01 | 2010-11-01 | |
| US61/456,127 | 2010-11-01 | ||
| PCT/US2011/058856 WO2012061443A2 (en) | 2010-11-01 | 2011-11-01 | Compositions of a peptide-based system for cell-specific targeting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016080278A Division JP2016171801A (ja) | 2010-11-01 | 2016-04-13 | 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504150A JP2014504150A (ja) | 2014-02-20 |
| JP2014504150A5 true JP2014504150A5 (enExample) | 2014-12-18 |
| JP6189215B2 JP6189215B2 (ja) | 2017-08-30 |
Family
ID=44971106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536936A Expired - Fee Related JP6189215B2 (ja) | 2010-11-01 | 2011-11-01 | 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物 |
| JP2016080278A Pending JP2016171801A (ja) | 2010-11-01 | 2016-04-13 | 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016080278A Pending JP2016171801A (ja) | 2010-11-01 | 2016-04-13 | 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8680045B2 (enExample) |
| EP (1) | EP2635308A2 (enExample) |
| JP (2) | JP6189215B2 (enExample) |
| KR (1) | KR20130103562A (enExample) |
| CN (1) | CN103313730B (enExample) |
| AU (2) | AU2011323508B2 (enExample) |
| BR (1) | BR112013010911A2 (enExample) |
| CA (1) | CA2816584A1 (enExample) |
| SG (2) | SG190088A1 (enExample) |
| WO (1) | WO2012061443A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US20130210747A1 (en) | 2012-02-13 | 2013-08-15 | University Of Southern California | Methods and Therapeutics Comprising Ligand-Targeted ELPs |
| WO2014026054A2 (en) | 2012-08-10 | 2014-02-13 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| EP3016531A4 (en) * | 2013-07-01 | 2017-05-10 | The Trustees Of Princeton University | Dietary supplements and composition for treating cancer |
| BR112017003986A2 (pt) | 2014-08-27 | 2018-02-27 | Peptimed Inc | composições e métodos anti-tumor |
| CA2970478A1 (en) | 2014-12-10 | 2016-06-16 | S-Aima Holding Company, Llc | Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides |
| US10385115B2 (en) | 2015-03-26 | 2019-08-20 | Duke University | Fibronectin type III domain-based fusion proteins |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN106632682A (zh) * | 2015-08-04 | 2017-05-10 | 清华大学 | 融合蛋白ifn-elp及其应用 |
| EA037478B1 (ru) | 2015-08-04 | 2021-04-01 | Дьюк Юниверсити | Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| CN109890833A (zh) | 2016-09-14 | 2019-06-14 | 杜克大学 | 用于递送亲水性药物的基于三嵌段多肽的纳米粒子 |
| EP3515928A4 (en) | 2016-09-23 | 2020-04-01 | Duke University | UNSTRUCTURED NON-REPITITIVE POLYPEPTIDES WITH LCST BEHAVIOR |
| CN106822036B (zh) * | 2016-12-15 | 2022-08-09 | 国家纳米科学中心 | 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法 |
| WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| US11642319B2 (en) * | 2017-03-24 | 2023-05-09 | The Regents Of The University Of Colorado | Targeted nanogels for urinary bladder therapies |
| US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| WO2019014190A1 (en) | 2017-07-10 | 2019-01-17 | Brown Kathlynn C | MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| US12257308B2 (en) | 2018-04-30 | 2025-03-25 | Duke University | Stimuli-responsive PEG-like polymer-based drug delivery platform |
| WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
| WO2020081716A2 (en) * | 2018-10-16 | 2020-04-23 | Texas Tech University System | Biomaterials for 3d cell growth and differentiation |
| JP2022545055A (ja) * | 2019-07-09 | 2022-10-25 | アライズ プレシジョン メディシン，インク． | ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| JP2023526328A (ja) | 2020-05-14 | 2023-06-21 | エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド | ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療 |
| CN117138067A (zh) * | 2022-05-23 | 2023-12-01 | 安徽医科大学 | 99mTc-DOTA-GVR及其制备方法与应用 |
| WO2024143785A1 (ko) * | 2022-12-27 | 2024-07-04 | 주식회사 넥스세라 | 엘라스틴 유사 폴리펩타이드 기반 재조합 단백질 제작 및 이의 동물세포 발현 플랫폼 |
| WO2025108141A1 (zh) * | 2023-11-20 | 2025-05-30 | 湖南中晟全肽生物科技股份有限公司 | 一种放射性标记的类弹性蛋白多肽及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| WO1993023569A1 (en) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| WO1996018736A2 (en) | 1994-12-13 | 1996-06-20 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| EP0998306A1 (en) | 1997-07-24 | 2000-05-10 | Inex Pharmaceuticals Corp. | Liposomal compositions for the delivery of nucleic acid catalysts |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| JP2003528024A (ja) | 1997-12-16 | 2003-09-24 | バレンティス・インコーポレーテッド | 製剤化された核酸分子の無針注入 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
| DE60033840D1 (de) | 1999-10-07 | 2007-04-19 | Avi Biopharma Inc | Antisense-zusammensetzungen und verfahren zur behandlung von krebs |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6852834B2 (en) | 2000-03-20 | 2005-02-08 | Ashutosh Chilkoti | Fusion peptides isolatable by phase transition |
| AR030426A1 (es) * | 2000-06-09 | 2003-08-20 | Ipk Inst Fuer Pflanzengenetik | Proteinas sinteticas de tela de arana y su expresion en plantas transgenicas |
| JP2005500833A (ja) * | 2001-06-25 | 2005-01-13 | ブアズーボ・アンパルトセルスカブ | 腫瘍学薬物の革新 |
| CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| JP5253159B2 (ja) * | 2005-06-24 | 2013-07-31 | デューク・ユニヴァーシティ | 熱応答性バイオポリマーに基づく直接的ドラッグデリバリーシステム |
| JP2009511613A (ja) * | 2005-10-17 | 2009-03-19 | エンカム ファーマシューティカルズ アクティーゼルスカブ | 神経細胞接着分子ｌ１のペプチド断片を含む新規ｆｇｆ受容体結合化合物 |
| US20100119529A1 (en) * | 2006-05-12 | 2010-05-13 | Furgeson Darin Y | Elastin-like polymer delivery vehicles |
| US8241623B1 (en) * | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2011
- 2011-11-01 JP JP2013536936A patent/JP6189215B2/ja not_active Expired - Fee Related
- 2011-11-01 WO PCT/US2011/058856 patent/WO2012061443A2/en not_active Ceased
- 2011-11-01 US US13/287,110 patent/US8680045B2/en active Active
- 2011-11-01 AU AU2011323508A patent/AU2011323508B2/en not_active Ceased
- 2011-11-01 EP EP11782511.7A patent/EP2635308A2/en not_active Withdrawn
- 2011-11-01 KR KR1020137013831A patent/KR20130103562A/ko not_active Ceased
- 2011-11-01 SG SG2013033451A patent/SG190088A1/en unknown
- 2011-11-01 CA CA2816584A patent/CA2816584A1/en not_active Abandoned
- 2011-11-01 SG SG10201508981YA patent/SG10201508981YA/en unknown
- 2011-11-01 CN CN201180059699.3A patent/CN103313730B/zh not_active Expired - Fee Related
- 2011-11-01 BR BR112013010911A patent/BR112013010911A2/pt not_active IP Right Cessation
-
2014
- 2014-02-07 US US14/175,798 patent/US9358308B2/en active Active - Reinstated
-
2016
- 2016-04-13 JP JP2016080278A patent/JP2016171801A/ja active Pending
-
2017
- 2017-07-24 AU AU2017208213A patent/AU2017208213A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504150A5 (enExample) | ||
| Dua et al. | Nucleic acid aptamers targeting cell-surface proteins | |
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| Sun et al. | Oligonucleotide aptamers: new tools for targeted cancer therapy | |
| JP2022101618A (ja) | 条件的活性型ポリペプチド | |
| CN110582302A (zh) | 用于核酸和/或蛋白有效负载递送的组合物和方法 | |
| CN112334156A (zh) | 用于亲和纯化的工程细胞外囊泡 | |
| US20230059921A1 (en) | Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents | |
| Yang et al. | Leveraging aptamers for targeted protein degradation | |
| US20240043844A1 (en) | FN3 Domain-siRNA Conjugates with Enzyme Replacement Therapy | |
| Vazquez et al. | Modular protein engineering in emerging cancer therapies | |
| Choi et al. | Efficient siRNA delivery into tumor cells by p19-YSA fusion protein | |
| US10640539B2 (en) | Recombinant protein-based method for the delivery of silencer RNA to target the brain | |
| Kubo et al. | Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity | |
| Winkler | Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides | |
| Geoghegan et al. | Gene silencing mediated by siRNA-binding fusion proteins is attenuated by double-stranded RNA-binding domain structure | |
| Chou et al. | Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo | |
| KR101253261B1 (ko) | ｓｉＲＮＡ 의 전달을 위한 재조합 단백질 및 이를 포함하는 조성물 | |
| US11535654B2 (en) | Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector | |
| Yang et al. | Production and characterization of a fusion peptide derived from the rabies virus glycoprotein (RVG29) | |
| Covarrubias-Zambrano et al. | Nano-inspired technologies for peptide delivery | |
| Jun et al. | Design of a multicomponent peptide-woven nanocomplex for delivery of siRNA | |
| KR20220117091A (ko) | 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도 | |
| Chaudhry | Peptide conjugates for microRNA-21 inhibition in glioblastoma multiforme | |
| WO2025042711A1 (en) | Engineered transferrin receptor binding peptides as well as methods of making and using the same |